Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -35,625 | -24,621 | -11,643 | -46,939 | -36,430 |
| Depreciation Amortization | -7 | -12 | 16 | 239 | 230 |
| Accounts payable and accrued liabilities | -88 | 640 | 266 | -1,456 | -1,569 |
| Other Working Capital | 1,221 | 2,578 | 684 | -1,423 | -1,516 |
| Other Operating Activity | 5,688 | 3,211 | 1,687 | 8,591 | 6,554 |
| Operating Cash Flow | $-28,811 | $-18,204 | $-8,990 | $-40,988 | $-32,731 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,320 | 9,201 | 8,785 | -29,837 | -36,506 |
| PPE Investments | -20 | -16 | -16 | -355 | -220 |
| Investing Cash Flow | $-1,340 | $9,185 | $8,769 | $-30,192 | $-36,726 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 22 | 6 | 1 | 65,270 | 65,098 |
| Financing Cash Flow | $22 | $6 | $1 | $65,270 | $65,098 |
| Beginning Cash Position | 39,196 | 39,196 | 39,196 | 45,106 | 45,106 |
| End Cash Position | 9,067 | 30,183 | 38,976 | 39,196 | 40,747 |
| Net Cash Flow | $-30,129 | $-9,013 | $-220 | $-5,910 | $-4,359 |
| Free Cash Flow | |||||
| Operating Cash Flow | -28,811 | -18,204 | -8,990 | -40,988 | -32,731 |
| Capital Expenditure | -20 | -16 | -16 | -355 | -220 |
| Free Cash Flow | -28,831 | -18,220 | -9,006 | -41,343 | -32,951 |